logo
AAT Bioquest

Matrix metalloproteinase 9 Inhibitors (IC50, Ki)

Structure
Compound Name
Standard Type
Standard Values (in nM)
(2R)-N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide;hydrochlorideIC506.8 [1]
(2R)-N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide;hydrochlorideKi8.0 [1]
IlomastatIC500.55 [1]
IlomastatKi0.57 [1], 0.69 [2]
MarimastatIC500.79 [1], 1.5 [2], 1.6 [3], 10000.0 [4]
MarimastatKi1.0 [1], 11.0 [2]
4-[4-(4-Chloro-phenoxy)-benzenesulfonylmethyl]-tetrahydro-pyran-4-carboxylic acid hydroxyamideIC500.11 [1], 2.0 [2], 3.0 [3]
4-[4-(4-Chloro-phenoxy)-benzenesulfonylmethyl]-tetrahydro-pyran-4-carboxylic acid hydroxyamideKi0.55 [1], 0.58 [2]
PrinomastatIC500.05 [1], 0.2 [2], 0.26 [3], 0.4 [4]
N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)acetamideIC50200.0 [1]
n-Hydroxy-2-[(4-methoxy-benzenesulfonyl)-pyridin-3-ylmethyl-amino]-3-methyl-benzamideIC505.0 [1], 5.01 [2]
BatimastatIC500.2 [1], 0.6 [2], 0.67 [3], 25.0 [4]
2-((4-Phenoxyphenylsulfonyl)methyl)thiiraneKi400.0 [1], 600.0 [2]
Mmp inhibitor IIIC501.8 [1], 2.7 [2]
Mmp inhibitor IIKi30.0 [1]
(2S)-2-[[4-(4-Methoxyphenyl)phenyl]sulfonylamino]-3-methylbutanoic acidIC50747.0 [1], 2187.76 [2], 2200.0 [3]
N-(3-Methoxybenzyl)-4-Oxo-3,4-Dihydroquinazoline-2-CarboxamideIC5010000.0 [1]
N-(4-(4-(Thiiran-2-ylmethylsulfonyl)phenoxy)phenyl)acetamideIC50529.1 [1]
N-(4-(4-(Thiiran-2-ylmethylsulfonyl)phenoxy)phenyl)acetamideKi130.0 [1]
(R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamideIC5012.0 [1]
(R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamideKi2.0 [1]
N-Isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acidIC504.8 [1], 5.9 [2], 34.0 [3]
CipemastatIC502.4 [1], 58.0 [2]
CipemastatKi59.0 [1]
N-Hydroxy-N~2~-[(4-Methoxyphenyl)sulfonyl]glycinamideIC50130.0 [1]
N-Hydroxy-N~2~-[(4-Methoxyphenyl)sulfonyl]glycinamideKi143.0 [1], 144.54 [2]
(2R)-2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxy-3-methylbutanamideKi27.0 [1]
(R)-N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamideIC506.7 [1]
CID 6914621IC5010340.0 [1]
CID 6914621Ki10340.0 [1]
CID 10370504IC50840.0 [1]
4-[(4-But-2-ynoxyphenyl)sulfonylmethyl]-N-hydroxy-1-propan-2-ylsulfonylpiperidine-4-carboxamideIC501670.0 [1]
N-Hydroxy-4-(4-phenylsulfanylphenyl)sulfonyl-1-prop-2-ynylpiperidine-4-carboxamideIC501.5 [1]
(2S,3R)-2-(Cyclopropylmethylamino)-N-hydroxy-N'-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(3-hydroxyphenyl)methyl]butanediamideKi4468.0 [1]
N-Hydroxy-2-[(4-nitro-benzyl)-pentafluorobenzenesulfonyl-amino]-acetamideKi0.6 [1]
(2S)-2-[[4-(4-Fluorophenyl)phenyl]sulfonylamino]-3-methylbutanoic acidIC5064000.0 [1], 64565.42 [2]
Benzyl 6-Benzyl-5,7-Dioxo-6,7-Dihydro-5h-[1,3]thiazolo[3,2-C]pyrimidine-2-CarboxylateIC5030000.0 [1], 100000.0 [2]
(2R,3R,4R,5S)-N,3,4,5-Tetrahydroxy-1-(4-phenoxyphenyl)sulfonylpiperidine-2-carboxamideKi0.06 [1]
N-Hydroxy-2-[[4-(4-methoxyphenyl)phenyl]methyl]-1,1-dioxo-1,2-thiazolidine-3-carboxamideKi46.7 [1]
(8S,11R,12S)-12-N-Hydroxy-8-N-(2-morpholin-4-yl-2-oxoethyl)-2,10-dioxo-11-[[4-[2-(trifluoromethyl)phenyl]phenyl]methyl]-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamideKi2000.0 [1]
N-Hydroxy-2-[(4-methoxy-benzenesulfonyl)-(4-nitro-benzyl)-amino]-acetamideKi30.9 [1], 31.0 [2]
N-Hydroxy-2-[(4-nitro-benzyl)-(nonafluorobutane-1-sulfonyl)-amino]-acetamideKi2.0 [1]
((4'-Chloro-[1,1'-biphenyl]-4-yl)sulfonyl)valineIC5015848.93 [1], 16000.0 [2]
(3R)-2-[Ethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamideKi5.05 [1]
(6S,7S)-N-Hydroxy-6-[(4-phenylpiperazin-1-yl)carbonyl]-5-azaspiro[2.5]octane-7-carboxamideIC50650.0 [1]
2-[Benzyl(4-methoxyphenylsulfonyl)amino]-3-methoxybenzenecarbohydroximic acidIC5022.91 [1], 23.0 [2]
2-[Benzyl(4-methoxyphenylsulfonyl)amino]-3-methylbenzenecarbohydroximic acidIC5022.91 [1], 23.0 [2]
2-[Benzyl(4-methoxyphenylsulfonyl)amino]-3-methylbenzenecarbohydroximic acidKi23.0 [1]
(2R)-2-[Benzyl-[4-(2-fluoroethoxy)phenyl]sulfonylamino]-N-hydroxy-3-methylbutanamideIC5050.0 [1]
1-[4-(4-Chlorophenoxy)phenyl]-1,7,9-triazaspiro[4.5]decane-2,6,8,10-tetroneKi0.7 [1], 0.72 [2]
2-[4-(2-Butynyloxy)phenylsulfonylamino]acetohydroximic acidIC50753.0 [1], 758.58 [2], 890.0 [3]
N-Hydroxy-N-[1-(2-hydroxyethoxy)-3-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpropan-2-yl]formamideIC500.3 [1]
N-[1-(1,4-Dioxaspiro[4.5]decan-8-yl)-2-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylethyl]-N-hydroxyformamideIC502.0 [1]
N-[(3S)-3,4-Dihydroxy-1-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylbutan-2-yl]-N-hydroxyformamideIC500.09 [1]
Caffeic acidIC5010.0 [1], 21.22 [2]
N-Hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochlorideIC5010.0 [1], 40.0 [2]
TanomastatIC50301.0 [1]
TanomastatKi301.0 [1]
(S)-2-(4'-Bromo-[1,1'-biphenyl]-4-ylsulfonamido)-3-methylbutanoic acidIC507900.0 [1], 7943.28 [2]
ApratastatIC5082.0 [1]
n-[3-(n'-Hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamideKi1.0 [1], 10.0 [2]
Unii-Q56UE7E40YIC50304.0 [1], 428.0 [2]
(R)-5-(6-Cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamideIC5010000.0 [1]
N-[(1S)-1-[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]-2-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylethyl]-N-hydroxyformamideIC500.5 [1], 1.4 [2]
2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxy-3-methylbutanamideKi26.92 [1], 27.0 [2]
Mmp-2/mmp-9 inhibitor iIC50240.0 [1], 2700.0 [2]
cis-2-Aminocyclohexylcarbamoylphosphonic acidIC5020000.0 [1]
(3R)-3-[[(2S)-1-[[(1S)-2-Methoxy-1-phenylethyl]amino]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-6-(3-methyl-4-phenylphenyl)hexanoic acidIC5030400.0 [1]
N-[(2S)-1-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(trifluoromethoxy)phenyl]phenoxy]propan-2-yl]-N-hydroxyformamideIC50120.0 [1]
2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxyacetamideKi41.69 [1], 42.0 [2]
D-Tryptophan, N-[[5-[2-(4-methylphenyl)ethynyl]-2-thienyl]sulfonyl]-IC509.6 [1], 23.0 [2]
Methylamino-phenylalanyl-leucyl-hydroxamic acidIC500.38 [1]
Methylamino-phenylalanyl-leucyl-hydroxamic acidKi1.4 [1]
N-Hydroxy-1-(2-methoxyethyl)-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpiperidine-4-carboxamideIC500.18 [1], 0.2 [2]
4-{[1-Methyl-2,4-Dioxo-6-(3-Phenylprop-1-Yn-1-Yl)-1,4-Dihydroquinazolin-3(2h)-Yl]methyl}benzoic AcidIC5030000.0 [1], 100000.0 [2]
(2R)-N'-Hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-2-[(3-hydroxyphenyl)methyl]butanediamideKi3324.0 [1]
(3R,4R)-N-Hydroxy-4-[[4-[[2-(trifluoromethyl)benzimidazol-1-yl]methyl]benzoyl]amino]oxane-3-carboxamideKi2128.0 [1], 10000.0 [2]
2-(Biphenyl-4-ylsulfonamido)-N-hydroxyacetamideIC5034.0 [1]
(6S,7R,10S)-6-N-Hydroxy-10-N-methyl-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-1(14),12,15-triene-6,10-dicarboxamideKi1.8 [1]
2-[Benzyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxypropanamideKi34.67 [1], 35.0 [2]
4-[4-(Thiirane-2-ylmethylsulfonyl)phenoxy]phenolKi160.0 [1]
(2S)-3-Methyl-2-[(4-phenylphenyl)sulfonylamino]butanoic acidIC5025703.96 [1], 26000.0 [2]
Hydroxamate analogue 22IC500.54 [1], 3.0 [2]
1-Cyclopropyl-N-hydroxy-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylpiperidine-4-carboxamideIC500.15 [1], 1.0 [2]
2-[Methyl[4-(2-butynyloxy)phenylsulfonyl]amino]-3-methyl-5-bromobenzohydroximic acidIC50304.0 [1]
L-Valine,N-[(4'-nitro[1,1'-biphenyl]-4-yl)sulfonyl]-IC5038000.0 [1], 38018.94 [2]
Tert-butyl (6S,9R,10S)-10-(hydroxycarbamoyl)-6-(methylcarbamoyl)-9-(2-methylpropyl)-8-oxo-1,7-diazacyclotridecane-1-carboxylateKi1.0 [1]
N-Hydroxy-2-(4-methoxyphenylsulfonyl)-2-(prop-2-ynyl)pent-4-ynamideIC50141.0 [1]
(R,E)-N-Hydroxy-2-(4-methoxyphenylsulfonyl)-2-methyl-5-phenylpent-4-enamideIC5016.0 [1]
(3S)-N-Hydroxy-4-(4-methoxyphenyl)sulfonyl-2,2-dimethyl-1,1-dioxo-1,4-thiazepane-3-carboxamideIC503.6 [1]
2-Allyl-N-hydroxy-2-(4-methoxyphenylsulfonyl)pent-4-enamideIC5035.0 [1]
2-Pyrimidinecarboxamide, hexahydro-N-hydroxy-1,3-bis((4-methoxyphenyl)sulfonyl)-IC503.9 [1]
2-[Benzyl(4-methoxyphenylsulfonyl)amino]benzenecarbohydroximic acidIC50645.65 [1], 650.0 [2]
4-(4-(Thiiran-2-ylmethylsulfonyl)phenoxy)phenyl methanesulfonateKi5.0 [1]
(6S,7S)-N-Hydroxy-6-(4-phenyl-3,6-dihydro-2H-pyridine-1-carbonyl)-5-azaspiro[2.5]octane-7-carboxamideIC50113.0 [1]
5-Methyl-5-(4-phenoxy-phenyl)-pyrimidine-2,4,6-trioneIC5052.0 [1]
5-Methyl-5-(4-phenoxy-phenyl)-pyrimidine-2,4,6-trioneKi52.0 [1]
2-[Methyl(4-methoxyphenylsulfonyl)amino]-3-methyl-5-bromobenzohydroximic acidIC5011.0 [1]
N-Hydroxy-2-[(2-nitro-benzyl)-(nonafluorobutane-1-sulfonyl)-amino]-propionamideKi4.37 [1], 4.4 [2]
N-Hydroxy-2-[(2-nitro-benzyl)-pentafluorobenzenesulfonyl-amino]-propionamideKi1.0 [1]



References

This online tool may be cited as follows

MLA

"Quest Database™ Matrix metalloproteinase 9 Inhibitors (IC50, Ki)." AAT Bioquest, Inc.21 Nov2024https://www.aatbio.com/data-sets/matrix-metalloproteinase-9-inhibitors-ic50-ki.

APA

AAT Bioquest, Inc. (2024November 21). Quest Database™ Matrix metalloproteinase 9 Inhibitors (IC50, Ki). AAT Bioquest. https://www.aatbio.com/data-sets/matrix-metalloproteinase-9-inhibitors-ic50-ki.
BibTeXEndNoteRefMan